

Lysiane Marthey

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9325972/lysiane-marthey-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17 papers	1,368 citations	13 h-index	17 g-index
17 ext. papers	1,725 ext. citations	6.5 avg, IF	3.78 L-index

#	Paper	IF	Citations
17	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 801-810	21.7	494
16	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 395-401	1.5	184
15	Olmesartan-associated enteropathy: results of a national survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1103-9	6.1	134
14	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015 , 113, 989-95	8.7	121
13	FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. <i>Annals of Surgical Oncology</i> , 2015 , 22, 295-301	3.1	119
12	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018 , 67, 2056-2067	19.2	109
11	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). <i>Digestive and Liver Disease</i> , 2018 , 50, 1257-1271	3.3	65
10	Diagnostic value of combining ^{125}I -choline and ^{18}F -FDG PET/CT in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 852-859	8.8	47
9	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 106, 106-114	7.5	30
8	Evaluation of two nutritional scoresXassociation with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. <i>European Journal of Cancer</i> , 2019 , 119, 35-43	7.5	15
7	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1393-1403.e1	6.9	15
6	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018 , 119, 424-428	8.7	15
5	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. <i>Digestive and Liver Disease</i> , 2016 , 48, 441-5	3.3	13
4	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , 2021 , 124, 1941-1948	8.7	5
3	Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101603	2.4	2
2	P366 Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI). <i>Journal of Crohns and Colitis</i> , 2018 , 12, S289-S290	1.5	
1	Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan-authorsXreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 473-474	6.1	

